Literature DB >> 20883472

Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage.

Andrea Huwiler1, Nataliya Kotelevets, Cuiyan Xin, Oleksandr Pastukhov, Josef Pfeilschifter, Uwe Zangemeister-Wittke.   

Abstract

BACKGROUND AND
PURPOSE: Sphingosine kinases (SK) catalyse the formation of sphingosine 1-phosphate, which is a key lipid mediator regulating cell responses such as proliferation, survival and migration. Here we have investigated the effect of targeted inhibition of SK-1 on cell damage and elucidated the mechanisms involved. EXPERIMENTAL APPROACH: Three human carcinoma cell lines (colon HCT-116, breast MDA-MB-231, lung NCI-H358) were used, which were either transduced with shRNA constructs to deplete SK-1, or treated with a SK-1 inhibitor. Cell growth and viability were assayed by [(3) H]thymidine incorporation and colony formation. Reactive oxygen species (ROS) were measured by fluorescence and apoptosis by annexin V with flow cytometry. Proteins were analysed by Western blotting. DNA damage was induced by doxorubicin. KEY
RESULTS: Knock-down of SK-1 by shRNA strongly inhibited DNA synthesis and colony formation of carcinoma cells. SK-1 knock-down (SK-1kd) cells revealed dysfunctional extracellular signal-regulated protein kinase and PKB/Akt cascades, and contained increased levels of ROS. After SK-1kd, treatment with doxorubicin increased DNA damage, measured by histone-2AX phosphorylation. Similar effects were found in cells with a SK-1 inhibitor and doxorubicin. The increased damage response in SK-1kd cells was accompanied by greater reduction of DNA synthesis and colony formation, and by more pronounced apoptosis. Addition of a NADPH oxidase inhibitor reduced the increased apoptosis in doxorubicin-treated SK-1kd cells. CONCLUSIONS AND IMPLICATIONS: SK-1kd in carcinoma cells triggered oxidative stress by increasing intracellular Ros production. Targeted inhibition of SK-1 represents a promising approach to sensitize cells to DNA damage and facilitate apoptosis upon doxorubicin treatment.
© 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20883472      PMCID: PMC3031071          DOI: 10.1111/j.1476-5381.2010.01053.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

Review 1.  Physiology and pathophysiology of sphingolipid metabolism and signaling.

Authors:  A Huwiler; T Kolter; J Pfeilschifter; K Sandhoff
Journal:  Biochim Biophys Acta       Date:  2000-05-31

2.  Guide to Receptors and Channels (GRAC), 4th Edition.

Authors: 
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

Review 3.  Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance.

Authors:  X Deng; S M Kornblau; P P Ruvolo; W S May
Journal:  J Natl Cancer Inst Monogr       Date:  2001

4.  Superoxide potently induces ceramide formation in glomerular endothelial cells.

Authors:  A Huwiler; B Böddinghaus; A Pautz; S Dorsch; R Franzen; V A Briner; V Brade; J Pfeilschifter
Journal:  Biochem Biophys Res Commun       Date:  2001-06-08       Impact factor: 3.575

5.  Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.

Authors:  A Bonni; A Brunet; A E West; S R Datta; M A Takasu; M E Greenberg
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

6.  The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes.

Authors:  J S Karliner; N Honbo; K Summers; M O Gray; E J Goetzl
Journal:  J Mol Cell Cardiol       Date:  2001-09       Impact factor: 5.000

7.  Doxorubicin induces ceramide and diacylglycerol accumulation in rat hepatocytes through independent routes.

Authors:  Rosa Martínez; Rosaura Navarro; Mercedes Lacort; José Ignacio Ruiz-Sanz; M Begoña Ruiz-Larrea
Journal:  Toxicol Lett       Date:  2009-07-14       Impact factor: 4.372

8.  Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion.

Authors:  Dai Shida; Xianjun Fang; Tomasz Kordula; Kazuaki Takabe; Sandrine Lépine; Sergio E Alvarez; Sheldon Milstien; Sarah Spiegel
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

9.  Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients.

Authors:  Wen Li; Chun-Ping Yu; Jin-tang Xia; Ling Zhang; Gui-Xiang Weng; Hai-qing Zheng; Qing-li Kong; Li-juan Hu; Mu-Sheng Zeng; Yi-xin Zeng; Mengfeng Li; Jun Li; Li-Bing Song
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

10.  Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression.

Authors:  Shuyu Ren; Andrea Babelova; Kristin Moreth; Cuiyan Xin; Wolfgang Eberhardt; Anke Doller; Hermann Pavenstädt; Liliana Schaefer; Josef Pfeilschifter; Andrea Huwiler
Journal:  Kidney Int       Date:  2009-08-05       Impact factor: 10.612

View more
  22 in total

Review 1.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

2.  Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells.

Authors:  Joanna Pyszko; Joanna B Strosznajder
Journal:  Mol Neurobiol       Date:  2014-01-09       Impact factor: 5.590

3.  Sphingosine kinase 1 downregulation is required for adaptation to serine deprivation.

Authors:  Jean-Philip Truman; Christian F Ruiz; Magali Trayssac; Cungui Mao; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.191

Review 4.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2012-07-16

5.  Hair Cell Loss Induced by Sphingosine and a Sphingosine Kinase Inhibitor in the Rat Cochlea.

Authors:  Kohsuke Tani; Keiji Tabuchi; Akira Hara
Journal:  Neurotox Res       Date:  2016-01       Impact factor: 3.911

Review 6.  Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Authors:  Dmitri Pchejetski; Torsten Böhler; Justin Stebbing; Jonathan Waxman
Journal:  Nat Rev Urol       Date:  2011-09-13       Impact factor: 14.432

Review 7.  Nuclear actions of insulin-like growth factor binding protein-3.

Authors:  Robert C Baxter
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

8.  The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death.

Authors:  Oleksandr Pastukhov; Stephanie Schwalm; Uwe Zangemeister-Wittke; Doriano Fabbro; Frederic Bornancin; Lukasz Japtok; Burkhard Kleuser; Josef Pfeilschifter; Andrea Huwiler
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

9.  The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells.

Authors:  David G Watson; Francesca Tonelli; Manal Alossaimi; Leon Williamson; Edmond Chan; Irina Gorshkova; Evgeny Berdyshev; Robert Bittman; Nigel J Pyne; Susan Pyne
Journal:  Cell Signal       Date:  2013-01-11       Impact factor: 4.315

10.  Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions.

Authors:  Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2013-08       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.